ArticleJournal of cancer prevention2025
High-density Lipoprotein Cholesterol and the Development of Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue.
Article in Journal of cancer prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, no studies have examined the effect of high-density lipoprotein cholesterol (HDL-C) on the development of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). We investigated, for the first time, the relationship between HDL-C and the risk of MALT lymphoma. In this nationwide population-based cohort study, 4.25 million cancer-free individuals that underwent a National General Health Examination and cancer screening in 2010 were enrolled and followed until the end of 2017. Subjects were classified into 5 groups based on HDL-C levels (< 30, 30-39, 40-49, 50-59, or ≥ 60 mg/dL). MALT lymphoma was diagnosed in 1,119 of the 4.25 million study subjects during the follow-up period. Subjects with the lowest HDL-C level (< 30 mg/dL) had a higher risk of MALT lymphoma (adjusted hazard ratio [aHR] 1.79, 95% CI 1.08-2.96) than those with a HDL-C level of 40 to 49 mg/dL, whereas those with the highest HDL-C level (≥ 60 mg/dL) had a lower risk of MALT lymphoma (aHR 0.84, 95% CI 0.71-0.99). Sensitivity analyses, excluding individuals who were diagnosed with MALT lymphoma within 2-year of follow-up, also revealed similar association. In subgroup analysis, the hazardous effect of low HDL-C on MALT lymphoma development was significant in females (aHR 2.31, 95% CI 1.13-4.72) but not in males. An unfavorable effect of low HDL-C on MALT lymphoma was significant in never smokers (aHR 2.20, 95% CI 1.19-4.05) but not in smokers. In conclusion, a low HDL-C level was found to be associated with an increased risk of MALT lymphoma particularly in females or never smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.